^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Esophageal Cancer

    Related cancers:
    1d
    ROSETTA GI 204: A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204) (clinicaltrials.gov)
    P2/3, N=690, Recruiting, Bristol-Myers Squibb | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    HER-2 negative
    |
    Opdivo (nivolumab) • 5-fluorouracil • pumitamig (BNT327)
    1d
    Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma. (clinicaltrials.gov)
    P3, N=752, Not yet recruiting, Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
    New P3 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • CLDN18 (Claudin 18)
    |
    HER-2 negative • HER-2 expression • CLDN18.2 positive • CLDN1 positive
    |
    Tevimbra (tislelizumab-jsgr) • capecitabine • oxaliplatin • tecotabart vedotin (LM-302)
    1d
    Adebrelimab Neoadjuvant Treatment for Resectable ESCC (clinicaltrials.gov)
    P=N/A, N=22, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital
    New trial
    |
    cisplatin • albumin-bound paclitaxel • TheraCIM (nimotuzumab) • AiRuiLi (adebrelimab)
    2d
    VAMP7 governs ferroptosis suppression and cisplatin resistance in esophageal cancer: a dual-targeting therapeutic paradigm. (PubMed, Cancer Cell Int)
    Therapeutically, co-administration of ferroptosis agonists (RSL3/Erastin) with cisplatin abrogated VAMP7-mediated resistance, evidenced by suppressed xenograft growth and amplified mitochondrial pathology in preclinical models. This work identifies VAMP7 as a novel ferroptosis-chemoresistance nexus in EC, offering a translational framework for overcoming cisplatin refractoriness through coordinated inhibition of VAMP7 signaling and ferroptosis potentiation.
    Journal
    |
    GPX4 (Glutathione Peroxidase 4)
    |
    cisplatin • erastin • RSL3
    2d
    TroFuse-015: A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015) (clinicaltrials.gov)
    P3, N=450, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    paclitaxel • docetaxel • irinotecan • Lonsurf (trifluridine/tipiracil) • Jiataile (sacituzumab tirumotecan)
    3d
    Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors (clinicaltrials.gov)
    P1, N=280, Recruiting, SystImmune Inc. | Trial completion date: Aug 2027 --> Apr 2029 | Trial primary completion date: Dec 2025 --> Dec 2028
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 amplification • HER-2 mutation • HER-2 expression
    |
    trastuzumab brengitecan (BL-M07D1)
    3d
    Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study (clinicaltrials.gov)
    P=N/A, N=64, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed
    Trial completion
    3d
    STOPGAP: Study of Sequential Systemic Therapy + Intraperitoneal Paclitaxel in Gastric/GEJ Peritoneal Carcinomatosis (clinicaltrials.gov)
    P2, N=40, Active, not recruiting, University of California, Irvine | Recruiting --> Active, not recruiting | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    paclitaxel • 5-fluorouracil • leucovorin calcium
    3d
    SHR-1701 Combined With Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, Ruijin Hospital
    New P2 trial
    |
    paclitaxel • capecitabine • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur) • retlirafusp alfa (SHR-1701)
    3d
    A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation (clinicaltrials.gov)
    P1, N=42, Terminated, Prelude Therapeutics | Trial completion date: Apr 2027 --> Jan 2026 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2026 --> Jan 2026; Sponsor decision
    Trial completion date • Trial termination • Trial primary completion date • First-in-human
    4d
    Chemoradiotherapy Following Immunotherapy Plus Chemotherapy for Locally-advanced Esophageal Squamous Cell Cancer (RICE) (clinicaltrials.gov)
    P2, N=50, Active, not recruiting, Shanghai Chest Hospital | Not yet recruiting --> Active, not recruiting | Trial primary completion date: Nov 2024 --> Oct 2026
    Enrollment closed • Trial primary completion date
    |
    carboplatin • albumin-bound paclitaxel
    4d
    KEYNOTE-G02: A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation (clinicaltrials.gov)
    P2, N=6, Terminated, Prelude Therapeutics | Trial completion date: Dec 2027 --> Jan 2026 | Active, not recruiting --> Terminated | Trial primary completion date: Aug 2027 --> Jan 2026; Sponsor decision
    Trial completion date • Trial termination • Trial primary completion date
    |
    SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4)
    |
    Keytruda (pembrolizumab) • PRT3789